A61K2039/6006

SMALLPOX VACCINE FOR CANCER TREATMENT
20240335530 · 2024-10-10 ·

Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response.

Protein-cell conjugate, preparation method and use thereof

The present invention pertains to immunology, biomedicine field, specifically relates to a protein-cell conjugate, which is characterized in that the protein and the cell are coupled via a bifunctional cross-linking agent. The present invention further relates to a preparation method and uses of the protein-cell conjugate. The protein-cell conjugate of the present invention can be used for prevention or treatment of many diseases, such as malignant tumors, infectious diseases and autoimmune diseases.

COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS

Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.

BACTERIAL AND VIRAL VACCINE STRATEGY
20180228885 · 2018-08-16 · ·

The present invention generally relates to compositions and methods for delivering a vaccine. The compositions and methods disclosed herein are particularly useful in making bacterial and viral vaccines.

MODIFIED YEAST-BRACHYURY IMMUNOTHERAPEUTIC COMPOSITIONS
20180214525 · 2018-08-02 ·

Disclosed are improved yeast-based immunotherapeutic compositions comprising modified Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.

GENETICALLY ENGINEERED CELL-DERIVED VACCINES
20240350629 · 2024-10-24 ·

The disclosure provides for compositions and methods comprising cell-derived vesicles induced from cells that have been genetically engineered or infected to express specific antigen(s), and uses thereof, including as a cell-free, cell-like vaccine.

Methods and compositions for treating breast cancer with dendritic cell vaccines

Disclosed are compositions and methods for treatment of breast cancer. Disclosed methods and compositions include dendritic cells loaded with cyclin B1 and WT-1 peptide antigens for immunotherapy. These dendritic cell vaccines are administered alone or in combination with other cancer therapies to improve outcomes. Disclosed methods also involve the use of therapeutic agents, such as anakinra, that block the IL-1 inflammation pathway. These agents are used in combination with chemotherapy and/or immunotherapy in treating breast cancer.

COMPOSITION INCLUDING ADULT PLURIPOTENT OLFACTORY STEM CELL, METHOD FOR ISOLATING PLURIPOTENT ADULT OLFACTORY STEM CELL, AND USE THEREOF

A composition including adult pluripotent olfactory stem cells is provided. The adult pluripotent olfactory stem cells are obtained by culturing a cell mixture from an olfactory tissue of a mammal in media containing growth factors and then isolating cells which express B-lymphoma moloney murine leukemia virus insertion region-1 (Bmi-1).

Compositions and methods of enhancing immune responses

Provided herein are Salmonella enteritidis 13A strains and compositions comprising these strains. Also provided are methods of enhancing an immune response against Influenza A and methods of reducing morbidity associated with an Influenza A infection. Methods of enhancing an immune response to a vaccine vector by expressing a polypeptide of CD154 capable of binding CD40 are also disclosed. Methods of developing a bacterial vaccine vector are disclosed. Methods of generating scarless site-specific mutations in a bacterium are also disclosed.

AUGMENTING THE IMMUNE RESPONSE BY PROMOTING CELL DEATH OF IMMUNE CELLS

Methods and products for producing an antigen specific immune response are provided. The methods involve administration of a caspase inhibitor to a subject.